tiletamine hydrochloride has been researched along with beta-Thalassemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aydinok, Y; Berk, G; Cohen, AR; Giardina, PJ; Jeglinski, BI; Kuo, KH; Kwiatkowski, JL; Neufeld, EJ; Pietropaolo, K; Saliba, AN; Taher, AT; Viprakasit, V | 1 |
1 trial(s) available for tiletamine hydrochloride and beta-Thalassemia
| Article | Year |
|---|---|
Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cyclohexanones; Dihydropyridines; Dose-Response Relationship, Drug; Humans; Iron Chelating Agents; Kidney Diseases; Middle Aged; Siderophores; Thiazoles; Young Adult | 2017 |